OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS
Equity Capital Raises
Equity Transaction Chart
Viridian publishes weekly data on equity capital raises in the Cannabis/CBD/Psychedelic industries. This data includes information about the company issuing equity (public/private, state/country location), deal size, deal structure, pricing, share information, deal implied valuation, and warrant information.
Week ended 03/07/2025
Week ended 03/07/2025
This Section is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
Equity Commentary
Week ended 03/07/2025
Equity Raises:
-
- On March 3, 2025, Organigram Holdings (OGI: Nasdaq), the seventh-largest Canadian LP by market cap, closed its third tranche of investment from BAT for $29.0M. This was the final tranche of the previously announced C$124.6M strategic equity investment from British American Tobacco (“BAT”)
- Most of the investment will be used to fund a strategic investment pool named Jupiter. The Jupiter Pool aims to accelerate Organigram’s growth through investments in both the U.S. and overseas.
- The tranche was priced at $2.25 per share in July 2023, substantially higher than today’s trading price.
- On March 3, 2025, Organigram Holdings (OGI: Nasdaq), the seventh-largest Canadian LP by market cap, closed its third tranche of investment from BAT for $29.0M. This was the final tranche of the previously announced C$124.6M strategic equity investment from British American Tobacco (“BAT”)
Public vs. Private Raises:
- Both capital raisers this week are public. Both trade in the U.S. (one on OTCQx and one on Nasdaq) and in Canada (One on TSX and one on Cboe).
Equity vs. Debt Cap Raises:
- Debt accounted for 74% of trailing 8-week capital raises. The ratio may go down if companies are able to utilize favorable regulatory-induced stock price increases to complete equity issues. However, equity pricing has remained stubbornly low while the cannabis debt capital markets have reopened.
Week ended 03/07/2025
Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more.
Weekly Valuation Tracker
Viridian highlights a specific industry sector and provides a deep dive into valuation metrics and comparable company valuations for public companies operating in that sector. The Weekly Valuation Tracker provides proprietary, actionable valuation data.
- Week ended 03/07/2025
This week’s valuation tracker focuses on the 7 U.S. MSOs with market cap over $500M in the Viridian Value Tracker database in gauge the valuation impact of the 2nd earnings that have been released so far, Green Thumb (GTII: CSE), Curaleaf (CURA: CSE), and Trulieve.
- Week ended 03/07/2025
This Chart is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more.
This Chart is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
Viridian publishes weekly insights on equity capital raises in the Cannabis/CBD/Psychedelic industries. These insights typically highlight the most interesting/meaningful equity transactions of that week, and commentary on market conditions, equity deal structures and investor groups.